直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
    • AI + Finnegan
    • Appeals, Issues, and Legal Strategy
    • Diligence, Licensing, and Opinions
    • Global IP Enforcement, Litigation, and Trials
    • Patent Office Invalidation Proceedings
    • Prosecution and Portfolio Management
    • Trademark and Brand Management
    • AI, Electronics, and Information Technology
    • Chemicals, Industrials, and Materials
    • Communications
    • Consumer Goods and Services
    • Energy
    • Hospitality, Gaming, and Leisure
    • Life Sciences
    • Transportation and Logistics
  • Experience

Life Sciences

About

Bringing new products to market is particularly challenging for companies in the life sciences sector. It can be a long and risk-filled pathway from the lab to the shelf, often requiring careful navigation through rigorous testing and regulatory compliance. To be viable and competitive, a company’s business plan must include a comprehensive and proactive intellectual property strategy—investors expect it and the marketplace demands it.

As IP attorneys and professionals working with innovators dedicated to creating life-saving and life-improving products, we see first-hand how deliberate and holistic IP asset protection makes the difference, particularly when it comes to enforcing rights to keep competitors at bay or defending against infringement allegations. We apply our science and engineering backgrounds and full scope IP-focused legal acumen, drawn from real life experience in litigation, prosecution, and counseling, to keep clients in business so they can keep making and collaborating on groundbreaking scientific discoveries and inspired technological applications.

Understanding the law, science, and technology

Finnegan advises clients on virtually every intellectual property issue, whether it is related to patents, trademarks, copyrights, or trade secrets. Our practice comprises experienced attorneys and professionals who have an in-depth understanding of the complex legal, technical, regulatory, and business issues faced by industries innovating in the life sciences.

We help with:

  • Litigating high value products
  • Developing and executing patent prosecution strategies
  • Aligning patent and regulatory strategies
  • Analyzing patent portfolios for opportunities and landscape mapping
  • Creating licensing programs
  • Conducting due diligence investigations
  • Instituting and defending post-grant review proceedings
  • Providing trademark services and advertising protection

Comprehensive legal, technical, and strategic experience protecting innovations

Our Life Sciences practice includes attorneys and professionals with degrees in relevant scientific disciplines such as biology, chemistry, biochemistry, medicine, pharmacology, biomedical engineering, or electrical engineering, as well as attorneys with extensive experience in brand management and protection. Many joined Finnegan after holding positions in industry, at universities, or as examiners with the U.S. Patent and Trademark Office.

Everyone in this industry

Industries

Artificial Intelligence (AI) and Machine Learning (ML)

Advancements in artificial intelligence (AI) present novel challenges for businesses looking to invest in intellectual property. Protecting those investments and understanding the innovation landscape is where Finnegan comes in.

View Artificial Intelligence (AI) and Machine Learning (ML)

Biologics

Introduced nearly ten years ago, the Biologics Price Competition and Innovation Act (BPCIA) opened the door for companies to seek U.S. Food and Drug Administration (FDA) approval to manufacture and sell biosimilar or interchangeable versions of brand name biological products.

View Biologics

Biotechnology

Finnegan works with biotech pioneers to develop and execute successful intellectual property strategies, including patenting ground-breaking advancements, enforcing patents in litigation, and defending against claims of infringement or ownership by others.

View Biotechnology

Branded Hatch-Waxman (ANDA) Litigation and Trials

Success in Abbreviated New Drug Application (ANDA) litigation in the U.S. often begins months or even years before a case is filed. Whether you are anticipating receipt of a Paragraph IV notice letter or still in late-stage clinical trials, it is never too early to start preparation.

View Branded Hatch-Waxman (ANDA) Litigation and Trials

Digital Health

Consumers have access to an ever-growing number of affordable and portable devices designed to provide metrics and details about personal health and lifestyle. In an increasingly connected world, this type of information can be invaluable in helping healthcare professionals provide higher levels of care.

View Digital Health

Medical Device and Diagnostics

Finnegan has the legal experience and technical expertise to help clients address the many issues that arise in developing, protecting, and commercializing medical device and diagnostic inventions.

View Medical Device and Diagnostics

Pharmaceutical

Even with billions of dollars invested in research and development, few drugs make it through clinical trials and stringent regulatory clearances necessary to get to market. For those that do, it is crucial that the companies have protected the intellectual property (IP) underlying new drugs and treatments.

View Pharmaceutical

Experience

Advised a global investment firm on patent and life sciences regulatory aspects in respect of medicines for rare diseases and specialty care products*

Advised a global investment firm on patent and life sciences regulatory aspects in respect of medicines for rare diseases and specialty care products.

Advised a global life sciences company on (non-)infringement issues relating to a chemistry-related patent covering an anti-cancer drug for treating leukemias*

Advised a global life sciences company on (non-)infringement issues relating to a chemistry-related patent covering an anti-cancer drug for treating leukemias.

Advised a pulmonary drug delivery company on (non-)infringement issues relating to inhalers*

Advised a pulmonary drug delivery company on (non-)infringement issues relating to inhalers.

Advised a leading private equity firm on patent litigation and life sciences regulatory aspects on its acquisition of a leading European pharmaceutical company*

Advised a leading private equity firm on patent litigation and life sciences regulatory aspects on its acquisition of a leading European pharmaceutical company.

Regeneron Pharmaceuticals Inc v. Kymab Ltd.*

Represented Regeneron against Kymab on patents covering a transgenic mouse platform for antibody discovery in its appeal.

[2020] UKSC 27, Appeal number: UKSC 2018/0131, Supreme Court of the United Kingdom

Represented a global pharmaceutical company against a generic company on a patent covering an injectable painkilling medicine for short-term pain relief*

Represented a global pharmaceutical company against a generic company on a patent covering an injectable painkilling medicine for short-term pain relief.

More

Insights

Webinar

Data and Market Exclusivity: An Update on China’s New Law and Comparisons to the US and Europe

November 19, 2026

Webinar

Conference

Broad's 3rd Annual Biotech IP Summit

November 10, 2026

Cambridge

Panel Discussion

Turning Research Into a Venture: An IP Roadmap – Fall

November 10, 2026

Boston

Conference

Life Sciences Patent Network North America Fall 2026

November 2-3, 2026

San Francisco

Conference

2026 TIPA International Symposium

October 30, 2026

Taipei City

Conference

LES 2026 Annual Meeting

October 18-21, 2026

San Diego

More

Upcoming Events

Conference

IP Life Sciences Forum 2026

December 13-15, 2026

Coral Gables

Seminar

Global Patent Strategies for Life Sciences and Chemical Innovations: Key Developments in Europe and the United States – Osaka

December 10, 2026

Osaka

Seminar

Global Patent Strategies for Life Sciences and Chemical Innovations: Key Developments in Europe and the United States – Tokyo

December 8, 2026

Tokyo

Conference

Atlantic Basin Conference on Chemistry 2026

December 6-9, 2026

Rio de Janeiro

News

Award/Ranking

15 Finnegan Partners Named 2027 IAM Strategy 300 Global Leaders

November 19, 2026

Award/Ranking

Best Lawyers Ranks Finnegan a Tier 1 Firm for Patent Litigation

November 5, 2026

Commentary

Oura Targets Ultrahuman’s Redesigned Smart Ring Following Import Ban

October 29, 2026

Award/Ranking

Finnegan Shortlisted for Two ALB Korea Law Awards 2026

October 23, 2026

Award/Ranking

Six Finnegan Partners Named to IAM 2027 Global Leaders Guide

October 21, 2026

Award/Ranking

Finnegan Wins “Hatch-Waxman Litigation Firm of the Year – Branded” and David Weingarten Wins “Patent Strategy Attorney of the Year (South)” at the LMG Life Sciences Americas Awards

September 11, 2026

More

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP